Drug
Ranolazine
Ranolazine: highest development phase Post-Market, developed by Gilead Sciences, Menarini. 3 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Gilead Sciences, Menarini
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ranolazine NCT01721967 | Post-Market | Hypertrophic Cardiomyopathy |
| Ranolazine NCT01534962 | Phase 2 | Persistent Atrial Fibrillation |
| Ranolazine NCT01163734 | Phase 2 | Diastolic Heart Failure |
Latest
No recent events.
Follow Ranolazine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.